Clinical trial · Interventional
Stereotactic Body Radiotherapy for Liver Tumors
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Liver Metastases and Primary Liver Tumors
NCT01347333CI-TRIAL-00043742completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary liver tumors such as hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Intrahepatic Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver Metastases | Cholangiocarcinoma | PROBABILISTIC | 0.70 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stereotactic body radiosurgery | Radiation | — | UNRESOLVED |
| Stereotactic Body Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- liver metastases
- description
- Oligometastases (1-3) with aggregate tumor diameter \< 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
- interventionNames
- Radiation: Stereotactic body radiosurgery
- type
- OTHER
- label
- Primary Liver Tumors
- description
- Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
- interventionNames
- Radiation: Stereotactic Body Radiotherapy
Primary outcomes (1)
- measure
- Local Tumor Recurrence Rate
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient age \>= 18 years * Zubrod performance status of 0-3 * Oligometastases (1-3) with aggregate tumor diameter \< 6 cm * Metastases from neuroendocrine tumors with functional endocrine syndromes for symptom palliation * Unresectable hepatocellular carcinoma (HCC) * Unresectable intrahepatic cholangiocarcinoma (IHCC) * Maximum tumor diameter \< 6 cm * Adequate liver function: Total bilirubin \< 3 mg/dL Serum albumin \> 2.5 g/dL Serum levels of liver enzymes \< 3 times the upper limit of normal Normal PT and PTT unless patient is receiving anticoagulant medication \- Signed study-specific consent form Exclusion Criteria: * Maximum tumor diameter \> 6 cm * Prior radiotherapy to the liver * Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown effects of RT on lactating females * Patients with psychiatric or addictive disorder that would preclude obtaining informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.